Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Neoplasms 19Stomach Neoplasms 15Colorectal Neoplasms 15Lung Neoplasms 13Endometrial Neoplasms 13Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 10Colonic Neoplasms 9Carcinoma, Hepatocellular 9Oropharyngeal Neoplasms 6Neoplasm Metastasis 6Multiple Myeloma 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Rectal Neoplasms 5Mouth Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Head and Neck Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4

Interventions

Radiotherapy 10Cisplatin 9pembrolizumab 6Surveys and Questionnaires 6Methods 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5fludarabine 4Papillomavirus Vaccines 4Early Intervention, Educational 4Cyclophosphamide 4Brachytherapy 4durvalumab 3aldesleukin 3Vaccines, Synthetic 3Vaccines 3Sentinel Lymph Node Biopsy 3Radiosurgery 3Radiation 3Platinum 3Palliative Care 3Paclitaxel 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Drug Therapy 3Carboplatin 3Bleomycin 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vulvar Neoplasms × Observation × Clear all
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡